[ad_1]
This article is over a month old and may contain outdated advice from authorities regarding coronary heart disease.
Stay up to date on the NRK overview or on the FHI website.
The night before Sunday, 21,600 doses of AstraZeneca coronary vaccine arrived in Norway.
The vaccination program prioritizes the oldest age groups first. However, because the vaccine is not recommended for people over 65 years of age due to insufficient documentation, doses should be administered to healthcare professionals.
NEW ASSESSMENT: – FHI should take the new reports arriving in AstraZeneca for a new assessment, says Lill Sverresdatter Larsen from the Norwegian Nurses Association.
Photo: Rune Stoltz Bertinussen / NTB
On Saturday night, AstraZeneca confirmed that its coronary vaccine likely only has limited protection against mild illness as a result of the new variant of the South African coronavirus.
This has led the union leader of the Norwegian Nurses Association to remove the magazine from his mouth:
– We want FHI to conduct comprehensive evaluations of AstraZeneca before sending it to healthcare professionals, especially based on new reports that the vaccine does not protect well enough against mild and moderate disease, nor necessarily against infection from a person. to another, Lill Sverresdatter Larsen tells NRK.
You want a vaccine that protects against future infections
– Do you think the FHI surveys are a shame?
– NIPH conducts evaluations on a constant, day-to-day basis. We also hope this will be done in connection with the new reports that have appeared about the AstraZeneca vaccine.
– Are you skeptical about using this vaccine tomorrow?
– We believe that it is important that health personnel are vaccinated with a type of vaccine that works particularly well for us to reduce infection from person to person, and also that health personnel are protected against mild and moderate diseases, says Larsen.
The union leader says that health workers are always in a high-risk group for contagion, so it is especially important that health workers receive a vaccine that works well and suits the group.
He notes that the Pfizer vaccine “works well.”
– Nurses being offered AstraZeneca at work tomorrow. Do you advise them to take it?
– Must follow FHI recommendations. But FHI should also take the new reports that arrive about AstraZeneca for a new evaluation, says Lill Sverresdatter Larsen.
FHI sees no reason to reconsider
CALM: – We have no reason to believe that some of the vaccines stand out in a particular good or bad direction, says Vaccine Manager Geir Bukholm at FHI.
Photo: Terje Pedersen / NTB
According to Vaccine Manager Geir Bukholm, FHI constantly monitors the effectiveness of vaccines against the various coronary variants.
He tells NRK that several of the vaccines are being questioned about the extent to which they provide full protection against the South African variant.
– We have no reason to believe that some of the vaccines are headed in a particular good or bad direction.
– How do you rate that information that arrived yesterday about AstraZeneca?
– We are very interested in knowing the dates around this. We know that there have been similar signals regarding the other vaccines. We follow this closely. It is clear that if there is any vaccine that has a particularly bad effect against different virus variants, we will assume the consequence of that.
– Is there a reason to be concerned about healthcare professionals who receive the AstraZeneca vaccine?
– Not with the information we have so far. There are several vaccines available. Everyone is effective. So it is the case that we constantly consider whether there should be any special problems related to certain vaccines. We do not have such information now.
– Do you see any reason to reconsider administering AstraZeneca to healthcare professionals?
– We don’t have that.
AstraZeneca, University of Oxford
The coronary vaccine developed at the University of Oxford prevents COVID-19 symptoms in 70 percent of cases, the company claims. In Norway, the vaccine is not recommended for people over 65 years of age.
The AZD1222 vaccine is based on the monkey ChAdOx1 virus. This virus has been modified so that it cannot make copies of itself, so it does not lead to disease. The researchers also changed the virus to carry additional information. The additional information causes your body to produce the so-called “spike protein” of the coronavirus.
What happens is the following: You get the vaccine in your body. The vaccine virus enters your cells. Inside the cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.
You have been vaccinated.
Biontech, Fosun Pharma and Pfizer
The German pharmaceutical company BioNTech reports that its coronary vaccine has been shown to be 95 percent effective. Norway started vaccination with this on December 27, 2020.
The BNT162b2 vaccine relies on your body’s system for building things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNAs or “messenger ribonucleic acids.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something alien to which it must react.
You have been vaccinated.
Johnson and Johnson
The vaccine is in phase 3 of development.
Ad26 vaccine. COV2.S is based on the ad26 virus. It is a cold virus that circulates among humans. This virus has been modified by researchers so that it does not cause disease in humans. It also carries an extra gene, a bit of extra information. The additional information causes your body to produce the so-called “spike protein” of the coronavirus.
What happens is the following:
You get the vaccine in your body. The vaccine virus enters your cells. Inside cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.
You have been vaccinated.
Novavax with partners
Novavax expects results in early 2021.
The NVX-CoV2373 vaccine is based on what are called nanoparticles. These are microscopic structures. The Novavax vaccine has nanoparticles that are primarily an extract from the Quillaja saponaria plant. This extract is used in much of the world as a food additive, but it also has medicinal properties. In addition, the vaccine particles are made up of cholesterol and fatty acids. The particles also carry the “spike protein” of the coronavirus. These nails are produced in genetically modified yeast cells and are added to the particles in the production process.
What happens is the following:
The vaccine works in two ways. Nanoparticles make your immune system more responsive, and cutting-edge proteins make your immune system react as if a real coronavirus has entered the body.
You have been vaccinated.
Modern
Moderna is approved in the EU and Norway. Modern vaccination is ongoing in Norway
The mRNA-1273 vaccine relies on your body’s system to build things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells constantly use for this purpose. These are called mRNAs or “messenger ribonucleic acids.”
What happens is the following:
The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something alien to which it must react.
You have been vaccinated.
In this phase, the vaccine is given to a small group of young, healthy people to see if the immune system responds. Researchers are also investigating whether it causes powerful and perhaps dangerous side effects. Also, based on the results, it is estimated how much vaccine should be administered.
In this phase, the vaccine is given to a larger group that is made up more broadly. The aim is to find variations in the response of the immune system and more data on side effects and the most reasonable amount of vaccine.
In this phase, it is investigated if the vaccine provides protection against the disease and if it causes more rare side effects. Several thousand people receive the vaccine and several thousand people receive a sham vaccine. Nobody knows who gets what. This is to ensure good scientific data.
The vaccine is ready for distribution.
The vaccine is approved for use in the EU and Norway.
South Africa suspends vaccination
According to a study from the University of Oxford, a single dose of the AstraZeneca vaccine provides 76 percent protection for up to 90 days. It also reduces the risk of infecting others by 67 percent.
On Saturday, however, AstraZeneca confirmed to Reuters that previous study results “have shown limited efficacy against mild disease” of the South African variant.
– However, we have not been able to adequately establish how effective it is against serious illnesses and hospitalizations, because the trial participants were predominantly healthy young adults, the spokesperson added.
None of the more than 2,000 in the study died or were hospitalized.
Preliminary results were leaked in the Financial Times newspaper. The study has not yet been peer-reviewed, but it would be published on Monday.
On Sunday, South African Health Minister Zweli Mkhize said they would wait to be vaccinated with the AstraZeneca vaccine until researchers did a new evaluation.
The statement came as a result of news that it may have limited effect on the South African variant of the virus, Reuters writes.
The AstraZeneca vaccine is the third approved vaccine in Norway.
In February, Norway is expected to receive just under 200,000 doses of AstraZeneca.
